Transaction · 0001797826-26-000006

Thornberry Nancy

Thornberry Nancy, DIR, reported an open-market or private sale at Denali Therapeutics Inc. involving 615.000000 shares for an estimated $14600.10. Reported holdings after the transaction were 19686.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SDIR
DNLIDenali Therapeutics Inc.
Filing timeSep 04
Trade dateSep 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$22.28
Pre-filing
1mo ago +3.9%1w ago +10.3%1d ago +4.4%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

DNLI price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
DNLI since 2026-09-04Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001797826-26-000006
Common Stock
Transaction date
Sep 02, 2026
Filed Sep 04, 2026, 09:02 PM · 2d delay
Shares
615 sh
$2.37k per share
Estimated value
-$1.46M
Computed from shares × price
Holdings after
19.6k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted June 3, 2026.

  2. F2

    The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.54 to $23.52 per share. Upon request by the Commission staff, the Issuer, or a…

  3. F3

    Includes 6,408 Unvested RSUs.

  4. F4

    The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.59 to $23.85 per share. Upon request by the Commission staff, the Issuer, or a…

Original filing · 0001797826-26-000006
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

DNLI